The pharmacodynamics of enoxaparin in percutaneous coronary intervention with precise rapid enoxaparin loading (PEPCI-PRE study)

Jack L. Martin · Edward T. A. Fry ·
Todd Martin · Trevor H. Atherley ·
Seth S. Martin · Marvin J. Slepian

Published online: 10 May 2009
© Springer Science+Business Media, LLC 2009

Erratum to: J Thromb Thrombolysis
DOI 10.1007/s11239-009-0326-2

In this article the Percent therapeutic value in the first column of Table 2 appear incorrectly. They appear correctly below.

Table 2 Pharmacodynamic data

	5 min	2 h	4 h	6 h	8 h
Percent therapeutic (0.5–1.8 IU/ml)	76	100	100	100	100
Anti-Xa levels IU/ml after enoxaparin 30 mg IV followed by 1 mg/kg SC ($n = 26$)	0.62 ± 0.23	0.94 ± 0.18	1.00 ± 0.17	0.89 ± 0.13	0.78 ± 0.23

The online version of the original article can be found under doi:[10.1007/s11239-009-0326-2](https://doi.org/10.1007/s11239-009-0326-2).

J. L. Martin (✉)
Main Line Health, Sharpe-Strumia Research Foundation,
Bryn Mawr Hospital, 130 S. Bryn Mawr Ave., Bryn Mawr,
PA 19010, USA
e-mail: MartinJ@mlhs.org

E. T. A. Fry
The Care Group, LLC, St. Vincent Hospital, Indianapolis, IN,
USA

T. Martin
Main Line Health, The Lankenau Hospital, Wynnewood, PA,
USA

T. H. Atherley
Newark Beth Israel Medical Center, Newark, NJ, USA

S. S. Martin
Department of Medicine, Duke University Medical Center,
Durham, NC, USA

M. J. Slepian
Sarver Heart Center, University of Arizona, Tucson, AZ, USA